NEXT FUNDS TOPIX 17 Pharmaceutical ETF

NEXT FUNDS TOPIX 17 Pharmaceutical ETF is offered by NEXT FUNDS, a leading player in the field of passive investments.

The total expense ratio of NEXT FUNDS TOPIX 17 Pharmaceutical ETF is 0.32%, which means that investors pay 32 JPY per 10,000 JPY in investment capital annually.

The ETF is listed in JPY.

European investors may incur additional costs for currency exchange and transaction fees.

No, NEXT FUNDS TOPIX 17 Pharmaceutical ETF does not comply with the EU UCITS investor protection directives.

The P/E ratio of NEXT FUNDS TOPIX 17 Pharmaceutical ETF is 25.33.

NEXT FUNDS TOPIX 17 Pharmaceutical ETF is domiciled in JP.

The fund was launched on 3/21/2008.

The NEXT FUNDS TOPIX 17 Pharmaceutical ETF mainly invests in Healthcare companies.

The NAV of NEXT FUNDS TOPIX 17 Pharmaceutical ETF amounts to 33.03 B JPY.

The price-to-book ratio is 1.926.

Investments can be made through brokers or financial institutions that provide access to trading ETFs.

The ETF is traded on the stock exchange, similar to stocks.

Yes, the ETF can be held in a regular securities account.

The ETF is suitable for both short-term and long-term investment strategies, depending on the investor's goals.

The ETF is valued on a daily stock exchange basis.

Information on dividends should be requested from the provider's website or your broker.

The risks include market fluctuations, currency risks, and the risk associated with smaller companies.

The ETF is obligated to report regularly and transparently on its investments.

The performance can be viewed on Eulerpool or directly on the provider's website.

Further information can be found on the official website of the provider.